


T, 9002



(IV)

wherein


R¹ is lower alkyl, aryl or arylalkyl;

R² is hydrogen, hydroxy, alkoxy, -CH₂OH, cyano, -C(O)OR⁷, -CO₂H, -CONH₂, tetrazole, -CH₂NH₂ or halogen;

R³ is hydrogen, alkyl, heterocycle or

R¹
cont.

T, 9003



R⁴ is hydrogen, alkyl or B;

R⁵, R^{5'}, R⁸, R^{8'} and R^{8''} are independently hydrogen, alkoxy, lower alkyl, halogen, -OH, -CN, -(CH₂)_nNR⁶COR⁷, -CON(R⁶)R^{6'}, -CON(R⁶)OR^{6'}, -CO₂R⁶, -SR⁷, -SOR⁷, -SO₂R⁷, -N(R⁶)SO₂R¹, -N(R⁶)R^{6'}, -NR⁶COR⁷, -OCH₂CON(R⁶)R^{6'}, -OCH₂CO₂R⁷ or aryl; or

R⁵ and R^{5'} or R⁸ and R^{8'} may together with the carbon atoms to which they are attached form an aryl or heterocycle;

R⁶ and R^{6'} are independently hydrogen or lower alkyl; and

R⁷ is lower alkyl;

R⁹ and R^{9'} are independently hydrogen, lower alkyl, alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl; or

R⁹ and R^{9'} may together with the nitrogen atom to which they are attached form a heterocycle;


A is a bond, -(CH₂)_n- or -CH(B)-, wherein n is an integer of 1, 2 or 3 and

B is -CN, -CON(R⁹)R^{9'}- or -CO₂R⁷;

with the proviso that when A is a bond or -(CH₂)_n- and R³ is hydrogen or unsubstituted alkyl, then R⁴ is B or substituted alkyl;

(b) a compound of formula (V) is represented by the following general formula:

wherein



n is 0 to 5;

m is 0 or 1;

r is 0 to 3;

A is pyridinyl;

R¹ is (1) hydroxy, (2) oxo, (3) halogen, (4) cyano, (5) NR⁸R⁸, (6) SR⁸, (7) trifluoromethyl, (8) C₁-C₁₀ alkyl, (9) OR⁸, (10) SO₂R⁹, (11) OCOR⁹, (12) NR⁸COR⁹, (13) COR⁹, (14) NR⁸SO₂R⁹, (15) NR⁸CO₂R⁸, or (16) C₁-C₁₀ alkyl substituted by hydroxy, halogen, cyano, NR⁸R⁸, SR⁸, trifluoromethyl, OR⁸, C₃-C₈ cycloalkyl, phenyl, NR⁸COR⁹, COR⁹, SO₂R⁹, OCOR⁹, NR⁸SO₂R⁹ or NR⁸CO₂R⁸;

R² and R³ are independently (1) hydrogen, (2) C₁-C₁₀ alkyl or (3) C₁-C₁₀ alkyl with 1 to 4 substituents selected from hydroxy, C₁-C₁₀ alkoxy, or halogen;

X is (1) -CH₂-, (2) -CH₂-, (3) -CH=CH- or (4) -CH₂O-;

R⁴ and R⁵ are independently (1) hydrogen, (2) C₁-C₁₀ alkyl, (3) halogen, (4) NHR⁸, (5) OR⁸, (6) SO₂R⁹ or (7) NHSO₂R⁹;

R⁶ is (1) hydrogen or (2) C₁-C₁₀ alkyl;

R⁷ is Z-(R^{1a})_n;

R^{1a} is (1) R¹, (2) C₃-C₈ cycloalkyl, (3) phenyl optionally substituted with up to 4 groups independently selected from R⁸, NR⁸R⁸, OR⁸, SR⁸ or halogen, or (4) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen, optionally

substituted with up to four groups independently selected from oxo, R^8 , NR^8R^8 , OR^8 , SR^8 , or halogen;


Z is (1) phenyl, (2) naphthyl, (3) or a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen, (4) a benzene ring fused to a C_3 - C_8 cycloalkyl ring, (5) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen, (6) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen, or (7) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur or nitrogen fused to a C_3 - C_8 cycloalkyl ring;

R'
cont.
 R^8 is (1) hydrogen, (2) C_1 - C_{10} alkyl, (3) C_3 - C_8 cycloalkyl, (4) Z optionally having 1 to 4 substituents selected from halogen, nitro, oxo, $NR^{10}R^{10}$, C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, C_1 - C_{10} alkylthio, and C_1 - C_{10} alkyl having 1 to 4 substituents selected from hydroxy, halogen, CO_2H , CO_2 - C_1 - C_{10} alkyl, SO_2 - C_1 - C_{10} alkyl, C_3 - C_8 cycloalkyl, C_1 - C_{10} alkoxy, or Z optionally substituted by from 1 to 3 halogen, C_1 - C_{10} alkyl or C_1 - C_{10} alkoxy, or (5) C_1 - C_{10} alkyl having 1 to 4 substituents selected from hydroxy, halogen, CO_2H , CO_2 - C_1 - C_{10} alkyl, SO_2 - C_1 - C_{10} alkyl, C_3 - C_8 cycloalkyl, C_1 - C_{10} alkoxy, C_1 - C_{10} alkyl, or Z optionally substituted by from 1 to 4 halogen, C_1 - C_{10} alkyl or C_1 - C_{10} alkoxy;

R^9 is (1) R^8 or (2) NR^8R^8 ; and

R^{10} is (1) C_1 - C_{10} alkyl, or (2) two R^{10} groups together with the N to which they are attached forming a 5 or 6-membered ring optionally substituted with C_1 - C_{10} alkyl;

(c) a compound of formula (VI) is:




wherein

X is hydrogen, halogen, trifluoromethyl or lower alkyl, and

R is hydrogen; lower alkyl which may have a suitable substituent selected from the group consisting of cyclo(C₃-C₇)alkyl, hydroxy, lower alkoxy, carboxy and lower alkoxycarbonyl; cyclo(C₃-C₇)alkyl or lower alkanoyl;

(d) a compound of formula (VII) is represented by the following general formula:



wherein

R¹ is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl, hydroxymethyl, methyl, methoxyl, amino, formamido, acetamido, methylsulphonylamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p-methoxybenzylamino group;

R² is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl group;

R³ is a hydrogen, chlorine or bromine atom or a hydroxyl group,

R⁴ is a hydrogen atom or a methyl group;

R⁵ is a hydrogen atom or a methyl group;


R⁶ is a hydrogen, fluorine or chlorine atom or a methyl, methoxyl or hydroxy group;

X is an oxygen atom or a bond;

Y is an alkylene group of up to 6 carbon atoms or a bond; and

Z is an alkylene, alkenylene or alkynylene group of up to 10 carbon atoms; and

(e) a compound of formula (VIII) is represented by the following general formula:



wherein

R is hydrogen or methyl,

R¹ is hydrogen, halogen, hydroxy, benzyloxy, amino or hydroxymethyl,

R² is hydrogen, hydroxymethyl, -NHR³, -SO₂NR⁴R^{4'} or nitro,

R³ is hydrogen, methyl, -SO₂R⁵, formyl or -CONHR⁶,

R⁴ and R^{4'} are independently hydrogen, lower alkyl or benzyl,

R⁵ is lower alkyl, benzyl or -NR⁴R^{4'},

R⁶ is hydrogen or lower alkyl,

R^{6'} is hydrogen or lower alkyl,

R⁹ is hydrogen, amino, acetylamino or hydroxy, and

X is N, O, S or methylene;

provided that when X is N, O or S,

then R⁹ is hydrogen, either R⁷ or R⁸ is hydrogen, and the other is hydrogen, amino, acetylamino or hydroxy; and

provided that when X is methylene,

then both R⁷ and R⁸ are hydrogen.

B1
cont.
21. (Amended) The method of Claim 10 comprising administering the compound of formula (IV) or a salt thereof.

B2
413. (Amended) The method of Claim 10, comprising administering the compound of formula (VI) or a salt thereof.

514. (Amended) The method of Claim 10, comprising administering the compound of formula (VII) or a salt, ester or amide thereof.

615. (Amended) The method of Claim 10, comprising administering the compound of formula (VIII) or a salt thereof.

B3
717. A method for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence comprising administering to a subject in need thereof an effective amount of the compound as defined in Claim 10 or a pharmaceutically acceptable salt thereof.

918. (Amended) A method for the prophylactic and/or the therapeutic treatment of nervous pollakiuria, neurogenic bladder dysfunction, nocturia, unstable bladder, cystospasm, chronic cystitis, chronic prostatitis, overflow incontinence, passive incontinence, reflex incontinence, urge incontinence, urinary stress incontinence comprising administering to a

subject in need thereof an effective amount of a compound as defined in Claim 10 or a pharmaceutically acceptable salt thereof.

B³
Cont.
10⁹ 19. (Amended) A commercial package comprising:
the compound as defined in Claim 10 and
written matter associated therewith,
wherein the written matter states that the pharmaceutical composition can or should
be used for preventing and/or treating dysuria.

11¹⁰ 20. (Amended) An article of manufacture comprising:
a packaging material and
the compound as defined in Claim 10,
wherein said packaging material comprises a label or a written material which
indicates that the compound defined in Claim 10 can or should be used for preventing and/or
treating dysuria.--

Add new Claims 21-35:

B⁴
15 21. (New) The method of Claim 10, comprising treating a subject having dysuria.
13 22. (New) The method of Claim 10, comprising treating a subject having pollakiuria.
14 23. (New) The method of Claim 10, comprising treating a subject having urinary
incontinence.
15 24. (New) The method of Claim 10, comprising treating a subject having neurogenic
bladder dysfunction.
16 25. (New) The method of Claim 10, comprising treating a subject having nervous
pollakiuria.
17 26. (New) The method of Claim 10, comprising treating a subject having nocturia.
18 27. (New) The method of Claim 10, comprising treating a subject having an unstable
bladder.
19 28. (New) The method of Claim 10, comprising treating a subject having
cystospasm. 29. (New) The method of Claim 10, comprising treating a subject having
chronic cystitis.
20 30. (New) The method of Claim 10, comprising treating a subject having chronic
prostatitis.